GNPX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.44%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $22.14

Genprex Insider Trading History Chart

Genprex Share Price & Price History

^$1.28

▲ +0.07 (5.79%)

As of 04/15/2026 05:00 PM ET

Days: 30 | 90 | 365

Genprex Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/21/2023	Catherine M Vaczy	EVP	Buy	10	$2,140.00	$21,400.00	132
4/21/2023	John Rodney Varner	CEO	Buy	9	$2,100.00	$18,900.00	10

SEC Filings (Institutional Ownership Changes) for Genprex (NASDAQ:GNPX)

14.05% of Genprex stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Genprex Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Susquehanna International Group LLP	340,056	$58K	0.0%	+11.7%	27.204%
2/12/2025	Geode Capital Management LLC	76,045	$65K	0.0%	+368.1%	0.894%
2/11/2025	Virtu Financial LLC	80,424	$68K	0.0%	+64.1%	0.945%
8/15/2024	Armistice Capital LLC	218,000	$0.41M	0.0%	+122.7%	10.386%
11/6/2023	AMH Equity Ltd	813,135	$0.32M	0.4%	N/A	1.369%
5/9/2023	Verus Capital Partners LLC	55,500	$51K	0.0%	-37.3%	0.107%
2/13/2023	Tcwp LLC	17,500	$25K	0.0%	N/A	0.036%
5/13/2022	TCG Advisory Services LLC	16,000	$36K	0.0%	N/A	0.033%
5/11/2022	GSA Capital Partners LLP	123,618	$0.28M	0.0%	-59.3%	0.258%
2/14/2022	GSA Capital Partners LLP	303,904	$0.40M	0.0%	-25.8%	0.636%

Data available starting January 2016

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Today's Range

Now: $1.28

$1.21

$1.30

50 Day Range

MA: $1.85

$1.15

$2.27

52 Week Range

Now: $1.28

$1.15

$55.00

Volume

340,799 shs

Average Volume

341,460 shs

Market Capitalization

$11.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Genprex?: Genprex's top insider shareholders include:
Catherine M Vaczy (EVP)
John Rodney Varner (CEO)
Jack A Roth (Major Shareholder)
Julien L Pham (COO)
Learn More about top insider investors at Genprex.